GlaxoSmithKline to acquire biotechnology company 35Pharma for $950 million

格隆汇2026/02/25 13:30

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gelonghui, February 25th | GlaxoSmithKline announced that it has agreed to acquire Canadian biotechnology company 35Pharma for $950 million in cash. This marks the second major deal reached by the company's new CEO, Luke Miels, to accelerate new drug development. 35Pharma's experimental pulmonary arterial hypertension drug HS235 will strengthen GlaxoSmithKline's future respiratory drug pipeline.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

UBS's latest research report provides a forward-looking analysis of Micron Technology for Q4 of fiscal year 2026 (August) and fiscal year 2027. The core logic points to a continuously widening supply-demand gap in the memory industry, with market focus gradually shifting from short-term trading momentum to cycle sustainability and capital returns.

智通财经•2026/09/26 08:41

Infineon to launch its semiconductor factory in Thailand on October 1, with an investment exceeding 48 billion Thai baht.

智通财经•2026/09/26 02:56

The more impressive AI agents become, the more valuable storage gets! SK hynix’s NAND business is preparing for a $100 billion IPO on the US stock market.

智通财经•2026/09/26 01:56

Solidigm is considering an IPO in the United States as early as next year, with a potential valuation of up to 100 billions dollars.

智通财经•2026/09/26 01:16